Pacira Pharmaceuticals (PCRX) Posts Q2 Loss of 27c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q2 EPS of ($0.27), $0.16 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $8.77 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals